<DOC>
	<DOC>NCT00766337</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.</brief_summary>
	<brief_title>Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis速 in Patients With Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosed with subfoveal choroidal neovascularization secondary to agerelated macular degeneration within six months of initial study visit, and may have been treated with up to 3 Lucentis速 (ranibizumab) or 3 Avastin速 (bevacizumab) injections with the last injection administered at least 4 weeks prior to the initial study visit, or is treatmentna誰ve Visual acuity of 20/40 to 20/200 in the study eye Any other ocular disease that could compromise vision in the study eye Presence of other causes of choroidal neovascularization other than secondary to agerelated macular degeneration</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>wet AMD</keyword>
</DOC>